Two Sigma Investments LP Makes New $159,000 Investment in ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Two Sigma Investments LP purchased a new stake in ClearPoint Neuro, Inc. (NASDAQ:CLPT) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 10,314 shares of the company’s stock, valued at approximately $159,000.

Other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in ClearPoint Neuro by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 1,248,393 shares of the company’s stock worth $19,200,000 after purchasing an additional 5,400 shares in the last quarter. Millennium Management LLC lifted its stake in shares of ClearPoint Neuro by 5.0% in the 4th quarter. Millennium Management LLC now owns 289,150 shares of the company’s stock valued at $4,447,000 after acquiring an additional 13,866 shares during the last quarter. D. E. Shaw & Co. Inc. boosted its holdings in shares of ClearPoint Neuro by 27.9% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 288,409 shares of the company’s stock valued at $4,436,000 after acquiring an additional 62,889 shares in the last quarter. Invesco Ltd. acquired a new stake in shares of ClearPoint Neuro during the 4th quarter valued at $3,814,000. Finally, Jane Street Group LLC grew its position in ClearPoint Neuro by 119.6% during the 4th quarter. Jane Street Group LLC now owns 222,307 shares of the company’s stock worth $3,419,000 after acquiring an additional 121,083 shares during the last quarter. 30.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on CLPT. Stifel Nicolaus upped their target price on ClearPoint Neuro from $19.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, April 1st. Wall Street Zen cut ClearPoint Neuro from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd.

ClearPoint Neuro Stock Performance

CLPT stock opened at $12.08 on Friday. The company has a market capitalization of $338.11 million, a P/E ratio of -17.51 and a beta of 0.93. The company has a fifty day moving average price of $12.79 and a 200-day moving average price of $14.31. ClearPoint Neuro, Inc. has a 52-week low of $5.11 and a 52-week high of $19.22.

ClearPoint Neuro (NASDAQ:CLPT) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.07). The company had revenue of $8.49 million during the quarter, compared to analyst estimates of $8.21 million. ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. As a group, sell-side analysts forecast that ClearPoint Neuro, Inc. will post -0.66 earnings per share for the current fiscal year.

Insider Transactions at ClearPoint Neuro

In other news, Director Timothy T. Richards sold 10,000 shares of the company’s stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $13.28, for a total value of $132,800.00. Following the sale, the director now directly owns 77,381 shares of the company’s stock, valued at approximately $1,027,619.68. This represents a 11.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Joseph Burnett sold 21,247 shares of the stock in a transaction on Monday, June 9th. The stock was sold at an average price of $13.29, for a total transaction of $282,372.63. Following the sale, the chief executive officer now owns 243,522 shares of the company’s stock, valued at approximately $3,236,407.38. This trade represents a 8.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.97% of the stock is owned by corporate insiders.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.